NAM
NVCR icon

Nissay Asset Management’s NovoCure NVCR Stock Holding History

Nissay Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,920
Closed -$412K – 772
2023
Q2 		$412K Sell
9,920
-182
-2% -$11.3K ﹤0.01% 713
2023
Q1 		$608K Sell
10,102
-404
-4% -$32.3K 0.01% 674
2022
Q4 		$771K Sell
10,506
-239
-2% -$18K 0.01% 646
2022
Q3 		$816K Buy
10,745
+436
+4% +$34K 0.01% 617
2022
Q2 		$716K Buy
10,309
+148
+1% +$11.1K 0.01% 635
2022
Q1 		$842K Buy
10,161
+208
+2% +$15.3K 0.01% 650
2021
Q4 		$747K Buy
9,953
+201
+2% +$20.2K 0.01% 683
2021
Q3 		$1.13M Buy
9,752
+461
+5% +$69.7K 0.01% 599
2021
Q2 		$2.06M Buy
9,291
+304
+3% +$59.1K 0.02% 440
2021
Q1 		$1.19M Sell
8,987
-161
-2% -$25.5K 0.01% 570
2020
Q4 		$1.58M Buy
+9,148
New +$1.25M 0.02% 467

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Nissay Asset Management's NVCR Position: Q3 2023 in Review

Nissay Asset Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 9,920 shares — an estimated $412K sold.

Nissay Asset Management first reported a position in NVCR in Q4 2020 and held it in 11 quarters. The position peaked at $2.06M in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • Nissay Asset Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • Nissay Asset Management sold 9,920 NovoCure shares in Q3 2023, an estimated $412K.
  • Nissay Asset Management first reported a position in NovoCure in Q4 2020 and held it in 11 quarters.
  • Nissay Asset Management's NovoCure position peaked at $2.06M in Q2 2021.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Nissay Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.